BackRecursion Pharmaceuticals Overview
Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Target Price

Analysts' average 12-month price target for Recursion Pharmaceuticals is $5.4.

Get informed when a big investor buys or sells

+ Follow

Share Price

$3.63

Average Target Price

$5.4048.8% upside

2 analysts in the last 4 months

High: $5.5 | Low: $5.3

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-17Morgan Stanley$5.346% upsideOpen
2026-05-14Morgan Stanley$5.551.5% upsideOpen
2025-12-17UBS$11203% upsideOpen
2025-12-17Morgan Stanley$11203% upsideOpen
2025-02-28Leerink Partners$665.3% upsideOpen
2024-09-04NeedhamGil Blum$11203% upsideOpen
2024-09-03KeyBancScott Schoenhaus$12230.6% upsideOpen
2024-09-03JefferiesDennis Ding$665.3% upsideOpen
2024-06-26KeyBancScott Schoenhaus$16340.8% upsideOpen

Recursion Pharmaceuticals (RXRX) FAQ

Recursion Pharmaceuticals posts a target price of $5.4. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $5.4 for RXRX means covering analysts, on average, see the stock 48.8% upside of $3.63 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for RXRX's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Recursion Pharmaceuticals's other metric pages and overview cover the third.

Judging Recursion Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $5.4 here, then scan peer and history charts to see if the gap is persistent.